By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on Eli Lilly (LLY) due to its high valuation, execution risks, and potential margin pressure from Pharmacy Benefit Managers (PBMs). Novo Nordisk (NVO) is seen as relatively undervalued, with its oral GLP-1 drugs posing a significant threat to LLY's dominance.
Risk: Margin compression due to PBM pressure and competition from Novo Nordisk's oral GLP-1 drugs.
Opportunity: Novo Nordisk's oral GLP-1 drugs and pipeline could erode Eli Lilly's dominance, presenting an investment opportunity in NVO.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Analysts project that the weight loss market will grow rapidly in the coming years. Investors looking to cash in on this may turn to the companies that lead this niche: Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). These pharmaceutical giants have moved in opposite directions on the market over the past year: Eli Lilly has gained 40%, while Novo Nordisk's shares have dropped 42%. But that doesn't tell us which is more likely to perform well over the medium term. Let's decide that by looking more deeply into each company.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Eli Lilly's weight loss lineup includes Zepbound, which is currently the best-selling medicine in this niche. The company also recently received approval for Foundayo. This oral GLP-1 therapy is helping it expand its addressable market and attract patients who were hesitant to use injectable drugs. Eli Lilly is posting outstanding revenue and earnings growth, partly thanks to its dominance in chronic weight management. In the first quarter, the company's revenue jumped 56% year over year to $19.8 billion. Its earnings per share soared 170% year over year to $8.26.
In addition to its current crop of medicines, Eli Lilly has a deep pipeline in weight management. One of the more promising candidates it is working on is called retatrutide, an investigational therapy that mimics the action of three gut hormones, which could lead to improved efficacy. Retatrutide has performed extremely well in clinical studies so far. Meanwhile, beyond its weight-loss lineup and pipeline, Eli Lilly has important products and candidates in other fields, including oncology, immunology, and neuroscience. So, Eli Lilly isn't just a weight loss stock.
Novo Nordisk was once the leader in the anti-obesity market. Now, the company is playing catch-up. However, several recent developments could help the Denmark-based drugmaker avoid being left in the dust by its competitor. Novo Nordisk launched its oral GLP-1, Wegovy pill, in January, months before Foundayo earned approval. Oral Wegovy has been a smashing success so far, with more than two million prescriptions as of the end of the first quarter. Meanwhile, the original injectable Wegovy continues to post decent sales growth, too.
Further, Novo Nordisk has earned approval for a high-dose formulation of Wegovy that is even more effective. This could help the company compete with Zepbound. Novo Nordisk also has attractive pipeline candidates, including its own triple agonist, UBT251. The company's amycretin, a dual agonist of the GLP-1 and amylin hormones, is also undergoing phase 3 studies in oral and subcutaneous formulations, while the company's CagriSema is expected to earn approval by year-end.
Novo Nordisk does not have a particularly impressive lineup or pipeline beyond diabetes and obesity, but the company could be one of the winners as the weight loss market continues to grow.
Eli Lilly generates higher revenue and earnings while growing both faster organically. Eli Lilly also has a stronger lineup -- with Zepbound's efficacy unmatched by any approved weight-loss drug so far -- and a pipeline in its core therapeutic area that is just as deep as Novo Nordisk's. True, Novo Nordisk's forward price-to-earnings of 13 looks much more attractive than Eli Lilly's 31.3. The healthcare sector's average is 17.4. However, Eli Lilly has earned a premium given its dominance in weight loss and its diversified portfolio that boasts attractive candidates in other areas. So, Eli Lilly is a much better buy right now.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $440,440! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,303,950!
Now, it’s worth noting Stock Advisor’s total average return is 959% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 16, 2026. *
Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Eli Lilly's current valuation leaves zero room for operational error, making it a high-risk play despite its clear clinical leadership."
The article presents a simplistic 'growth vs. value' narrative that ignores the massive supply-chain and manufacturing bottleneck risks for both LLY and NVO. Eli Lilly’s 31.3x forward P/E is pricing in near-perfect execution, yet the company faces significant margin pressure as it scales production for Zepbound and Mounjaro. Conversely, the article’s claim that Novo Nordisk has dropped 42% is factually misleading or potentially based on a specific ADR structure misrepresentation, as NVO has remained relatively resilient. The real story isn't just clinical efficacy, but the 'moat' built through manufacturing capacity. I am cautious on LLY at these valuations, as any earnings miss or supply disruption will trigger a sharp multiple compression.
If GLP-1 demand continues to outstrip supply for the next 36 months, the pricing power of both firms effectively renders current valuation multiples irrelevant as they print cash.
"LLY's 31x multiple assumes durable competitive moat in obesity that oral GLP-1 adoption and NVO's pipeline are actively eroding; NVO at 13x offers asymmetric upside if market consolidates toward parity rather than winner-take-most."
The article's conclusion—that LLY's 31.3x forward P/E is justified by dominance—rests on a fragile assumption: sustained pricing power and market share in a category where efficacy gaps are narrowing fast. Novo's oral Wegovy hit 2M+ prescriptions in Q1 alone; high-dose formulations and pipeline candidates (UBT251, amycretin) suggest the moat is eroding. LLY's 170% EPS growth is real but partly reflects scarcity pricing that won't survive competition. NVO trades at 13x forward—a 58% discount—which may reflect not just pipeline risk but genuine undervaluation if oral GLP-1 adoption accelerates. The article ignores manufacturing constraints, payer resistance to premium pricing, and the possibility that market share stabilizes closer to 50-50 than LLY's current lead suggests.
If LLY's retatrutide triple agonist proves meaningfully superior in real-world use and maintains pricing at $15k+/year while competitors commoditize, the valuation gap widens further—and NVO's pipeline may simply be too late to matter.
"Lilly's valuation premium assumes sustained market leadership that Novo's imminent pipeline catalysts are positioned to challenge within 12 months."
The article's conclusion that Lilly deserves its 31.3x forward P/E premium over Novo's 13x overlooks execution risks in Lilly's pipeline and the speed of Novo's catch-up. Zepbound leads today, but Novo's high-dose Wegovy, oral launch already at 2M prescriptions, and CagriSema approval expected by year-end create multiple near-term catalysts that could erode Lilly's dominance faster than priced in. Lilly's diversification into oncology and neuroscience is real but secondary to the obesity franchise that drives most of its growth narrative.
Lilly's retatrutide triple agonist has shown superior efficacy in trials so far, and any delay in Novo's approvals would let Lilly extend its lead long enough to justify the multiple.
"Lilly's current dominance and premium valuation are at risk of being eroded by faster-than-expected Novo competition and potential payer/safety headwinds."
This piece over-weights Lilly's current lead in weight management while glossing over two major risks: (1) valuation risk—Lilly trades at a steep forward multiple (~31x) versus Novo (~13x), meaning any growth deceleration could trigger multiple compression; (2) competitive risk—the combo of Novo's oral Wegovy and a high-dose Wegovy line could close Lilly's lead faster than the article suggests. Additional caveats include payer access and potential long-term safety scrutiny for GLP-1 drugs, plus Lilly's aspirational retatrutide program which is unproven at scale. If growth slows or supply/payer dynamics bite, the Lilly premium may erode.
Novo could rapidly close the gap through its oral Wegovy and higher-dose formulations, and Lilly's prized position may prove temporary if safety, pricing, or reimbursement headwinds intensify.
"The market is ignoring the inevitable margin compression caused by PBM-driven pricing pressure as GLP-1s transition to mass-market coverage."
Claude and Grok are fixated on clinical efficacy, but you are all ignoring the 'payer cliff.' Both LLY and NVO are facing massive, looming pressure from PBMs (Pharmacy Benefit Managers) to slash net prices. As GLP-1s move from niche to mass-market, the current $1,000+ monthly list price is unsustainable. The real risk isn't just competition; it's a systemic reimbursement squeeze that will compress margins for both firms, regardless of whose molecule is slightly more potent.
"Payer pressure is symmetric; it doesn't resolve why Lilly commands a 2.4x multiple premium if both face the same margin headwind."
Gemini's payer cliff is real, but the timeline matters enormously. Mass-market adoption takes 3-5 years; current list prices sustain through 2026-27 at minimum. More critically: Lilly's oncology portfolio (VERZENIO, CYRAMZA) generates 40%+ of EBITDA and isn't GLP-1 exposed. A reimbursement squeeze hits both firms equally, so it doesn't explain the 18-point P/E gap. The gap reflects execution risk, not systemic risk. Novo's pipeline delay is the real arbitrage.
"Payer price cuts will compress Lilly's premium valuation more than Novo's due to heavier GLP-1 growth dependence."
Claude's claim that reimbursement pressure hits both equally ignores asymmetric exposure. Lilly derives the bulk of its growth narrative and 31x multiple from GLP-1s, while oncology remains a smaller, slower-growing buffer. A 20-30% net price cut by 2027 via PBMs would force steeper multiple compression for LLY than for NVO at 13x, even if pipeline execution matches expectations.
"Payer-cliff risk is asymmetric: Lilly’s premium hinges on GLP-1 exclusivity and margins, making it more vulnerable to rebates and net-price declines than Novo's Wegovy-centric growth."
Gemini's payer-cliff argument is the most compelling angle, but the risk is not symmetric. A systemic reimbursement squeeze will pressure net margins, yet Lilly's GLP-1 moat is more fragile than implied by a simple 'both hit equally' thesis. Novo benefits from unit economics on Wegovy and a faster path to volume growth via oral delivery, so the 18-point P/E gap may re-rate differently than peers expect if rebates bite Lilly more.
The panel consensus is bearish on Eli Lilly (LLY) due to its high valuation, execution risks, and potential margin pressure from Pharmacy Benefit Managers (PBMs). Novo Nordisk (NVO) is seen as relatively undervalued, with its oral GLP-1 drugs posing a significant threat to LLY's dominance.
Novo Nordisk's oral GLP-1 drugs and pipeline could erode Eli Lilly's dominance, presenting an investment opportunity in NVO.
Margin compression due to PBM pressure and competition from Novo Nordisk's oral GLP-1 drugs.